A phase 4 randomized double-blind study comparing Sanofi's protein-based COVID-19 vaccine Nuvaxovid with Moderna's mRNA vaccine mNEXSPIKE found Nuvaxovid to have significantly fewer and milder side effects. The study of 1,000 US adults showed systemic side effects that disrupt daily activities were over 50% less frequent with Nuvaxovid. Local injection site reactions were also much lower. These findings could improve vaccine acceptance and yearly booster uptake as concerns about side effects remain a major barrier to COVID-19 vaccination. Sanofi plans to expand Nuvaxovid availability globally in 2026.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
